SEC Form 4 · accession 0001127602-17-017796
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John W Madigan
Director
Period of report
May 9, 2017
Accepted (ET)
May 11, 2017 · 6:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 9, 2017 | M | 1,787 | — | A | 18,548 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | May 9, 2017 | M | 1,787 | D | — | — | Common Stock | 1,787 | 0 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F2100% of the restricted stock units vested on May 9, 2017.